Veteran Citius CEO Uses All-In Approach to Bring New Treatments to Market healthleadersmedia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healthleadersmedia.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development.
/PRNewswire/ Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development.
Published: Apr 14, 2021
Jeffrey Wasserman, JD, named General Counsel
WALTHAM, Mass. (BUSINESS WIRE) Pyramid Biosciences, Inc., a Boston-based, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, today announced two new appointments to the leadership team.
Brian Lestini, MD, PhD, has joined the company as Chief Medical Officer, where he will oversee the advancement and expansion of the Company s clinical pipeline. Dr. Lestini joins the Company from Bristol-Myers Squibb (NYSE: BMY), where he most recently was Vice President and Development Leader for the relatlimab (anti-LAG3) checkpoint inhibitor program. In this capacity, Dr. Lestini oversaw the development and commercialization strategy for this novel immune-oncology agent across a wide range of tumors. Dr. Lestini brings over a decade of early- and late-stage clinical development leadership experience in Oncology, includ